Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

[1]  O. Kehoe,et al.  Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors , 2022, Inflammopharmacology.

[2]  M. D. de Wit,et al.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 , 2022, Nature Reviews Rheumatology.

[3]  D. Gladman,et al.  POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS , 2022, Annals of the Rheumatic Diseases.

[4]  T. Sornasse,et al.  OP0024 DIFFERENTIATION BETWEEN IL-6 AND IL-17 PATHWAY INHIBITION IN RELATIONSHIP WITH CLINICAL OUTCOMES IN NON-BIOLOGICAL DMARD-IR AND BIOLOGICAL DMARD-IR PSORIATIC ARTHRITIS PATIENTS TREATED WITH UPADACITINIB IN SELECT-PsA 1 AND SELECT-PsA 2 STUDIES , 2022, Annals of the Rheumatic Diseases.

[5]  S. Nakayamada,et al.  Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study , 2022, Arthritis Research & Therapy.

[6]  L. Coates,et al.  Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) , 2021, Annals of the Rheumatic Diseases.

[7]  K. Leander,et al.  Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials , 2021, RMD Open.

[8]  S. Pennington,et al.  Applying precision medicine to unmet clinical needs in psoriatic disease , 2020, Nature Reviews Rheumatology.

[9]  A. Gottlieb,et al.  Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.

[10]  A. Deodhar,et al.  Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.

[11]  N. Wei,et al.  Psoriatic Arthritis: What is Happening at the Joint? , 2019, Rheumatology and Therapy.

[12]  A. Gottlieb,et al.  Psoriatic arthritis for dermatologists , 2019, The Journal of dermatological treatment.

[13]  D. Gladman,et al.  Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab , 2019, The Journal of Rheumatology.

[14]  A. Gottlieb,et al.  Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta‐analysis of observational and clinical studies , 2019, Journal of the American Academy of Dermatology.

[15]  Jasvinder A. Singh,et al.  2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis , 2018, Arthritis care & research.

[16]  S. Nakayamada,et al.  OP0321 Precision medicine using different biological dmards based on characteristic phenotypes of peripheral t helper cells in psoriatic arthritis , 2018, Rheumatology.

[17]  V. Chandran,et al.  Exploring the Psoriatic Arthritis Proteome in Search of Novel Biomarkers , 2018, Proteomes.

[18]  L. Coates,et al.  Considerations for the definition of remission criteria in psoriatic arthritis. , 2017, Seminars in arthritis and rheumatism.

[19]  D. Gladman,et al.  Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors , 2017, The New England journal of medicine.

[20]  U. Wagner,et al.  Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial , 2017, The Lancet.

[21]  J. Greenberg,et al.  Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry , 2017, Clinical Rheumatology.

[22]  P. Mease,et al.  Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study , 2016, The Journal of Rheumatology.

[23]  P. Mease.  A short history of biological therapy for psoriatic arthritis. , 2015, Clinical and experimental rheumatology.

[24]  S. Feldman,et al.  The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials , 2015, The Journal of dermatological treatment.

[25]  A. Gottlieb,et al.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.

[26]  D. Gladman,et al.  Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis , 2013, The Journal of Rheumatology.

[27]  A. Loft,et al.  Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. , 2013, Arthritis and rheumatism.

[28]  D. Gladman,et al.  Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab , 2012, Annals of the rheumatic diseases.

[29]  D. Gladman,et al.  The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project) , 2012, Annals of the rheumatic diseases.

[30]  B. Bresnihan,et al.  Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. , 2012, Arthritis and rheumatism.

[31]  A. Kavanaugh,et al.  Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis , 2010, Annals of the rheumatic diseases.

[32]  D. Symmons,et al.  Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register , 2009, Arthritis research & therapy.

[33]  M. Dougados,et al.  Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate , 2008, Annals of the rheumatic diseases.

[34]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[35]  F. Salaffi,et al.  An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. , 2019, Clinical and experimental rheumatology.

[36]  I. McInnes,et al.  Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme. , 2019, Arthritis & rheumatology.

[37]  S. Rantapää Dahlqvist,et al.  Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? , 2009, Clinical and experimental rheumatology.

[38]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[39]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[40]  H. Holman,et al.  Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.

[41]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.

[42]  D. Gladman,et al.  Open Access Research Article Risk Factors for Radiographic Progression in Psoriatic Arthritis: Subanalysis of the Randomized Controlled Trial Adept , 2022 .